Maxim Group raised the price target for the Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021. We previously noted in another research note published on November 17, 2020 by Maxim Group that downgraded the stock from a Buy to a Hold for BCLI stock. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by Maxim Group, who disclosed in a research note on December 22, 2015, to Buy and set the price objective to $5.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.37 during the last quarter as opposed to a consensus estimate of -$0.43, which indicates the company beat its estimate by $0.06, which implies that the company surprised the market by 14.00%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.26. This is an average of 2 analysts’ earnings, where the high earnings per share estimate is -$0.25 and the low earnings per share estimate is -$0.27.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) raised 3.06% to close Wednesday’s market session at $4.04, higher as compared to yesterday’s close. The stock price fluctuated between $3.8601 and $4.75 throughout the trading session with the volume trading being 9777703 shares, which represented a significant variation when compared to the three months average volume of 1.09 million shares. The firm’s stock price fluctuated -6.48% within the last five trades and -4.04% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -72.31% in the last 6 months and -22.31% was subtracted to its value over the previous 3 months. BCLI stock is trading at a margin of 0.96%, -22.78% and -57.68% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, BCLI deals in the Healthcare domain. The stock is trading -77.49 percent below its 52-week high and 30.32 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 78. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Brainstorm Cell Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $137.08 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 3.81, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 19.77 percent of Brainstorm Cell Therapeutics Inc. shares are owned by insiders, and 23.10 percent are held by financial institutions. Setboun David, the EVP and COO at Brainstorm Cell Therapeutics Inc. (BCLI) has bought 5,000 shares of firm on Jul 16 at a price of $12.95 against the total amount of $64740.0. In another inside trade, ACC International Holdings Ltd, Member of 10% owner group of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) sold 7,823 shares of the firm on Jul 16 for a total worth of $0.11 million at a price of $13.47. An inside trade which took place on Jul 15, Director of Brainstorm Cell Therapeutics Inc. Abbhi Sankesh bought 46,779 shares of firm against total price of $0.61 million at the cost of $12.99 per share.